$REEMF
RARE ELEMENT RESOURCES LTD

2023 Q4 Form 10-Q Financial Statement

#000141980623000036 Filed on November 08, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $827.0K $646.0K
YoY Change -27.01% -30.16%
% of Gross Profit
Research & Development $2.059M $2.508M
YoY Change 9.06% 225.71%
% of Gross Profit
Depreciation & Amortization $1.000K $25.00K
YoY Change
% of Gross Profit
Operating Expenses $2.912M $3.179M
YoY Change -1.19% 84.83%
Operating Profit
YoY Change
Interest Expense $79.00K $7.000K
YoY Change -33.61% -91.03%
% of Operating Profit
Other Income/Expense, Net $1.929M $53.00K
YoY Change -2816.9% 253.33%
Pretax Income -$904.0K -$3.126M
YoY Change -68.82% 83.34%
Income Tax
% Of Pretax Income
Net Earnings -$904.0K -$3.126M
YoY Change -68.82% 83.34%
Net Earnings / Revenue
Basic Earnings Per Share -$0.01
Diluted Earnings Per Share $0.00 -$0.01
COMMON SHARES
Basic Shares Outstanding 212.9M 212.7M
Diluted Shares Outstanding 212.8M

Balance Sheet

Concept 2023 Q4 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $3.633M $6.593M
YoY Change -76.6% -64.94%
Cash & Equivalents $3.633M $6.593M
Short-Term Investments
Other Short-Term Assets $3.938M $3.506M
YoY Change 72.57% 106.6%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $9.750M $10.47M
YoY Change -45.77% -49.26%
LONG-TERM ASSETS
Property, Plant & Equipment $29.00K $30.00K
YoY Change 93.33% 100.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $186.0K $183.0K
YoY Change
Total Long-Term Assets $994.0K $1.018M
YoY Change 11.94% 11.5%
TOTAL ASSETS
Total Short-Term Assets $9.750M $10.47M
Total Long-Term Assets $994.0K $1.018M
Total Assets $10.74M $11.49M
YoY Change -43.05% -46.69%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $291.0K $221.0K
YoY Change 28.19% -52.58%
Accrued Expenses $111.0K $128.0K
YoY Change -10.48% 3.23%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.941M $349.0K
YoY Change 452.99% -40.85%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $366.0K $1.868M
YoY Change -76.85% 19.9%
Total Long-Term Liabilities $366.0K $1.868M
YoY Change -76.85% 19.9%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.941M $349.0K
Total Long-Term Liabilities $366.0K $1.868M
Total Liabilities $2.307M $2.217M
YoY Change 19.41% 3.21%
SHAREHOLDERS EQUITY
Retained Earnings -$157.6M -$156.7M
YoY Change 6.05% 7.54%
Common Stock $136.9M $136.9M
YoY Change 0.02% 0.02%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $8.437M $9.268M
YoY Change
Total Liabilities & Shareholders Equity $10.74M $11.49M
YoY Change -43.05% -46.69%

Cashflow Statement

Concept 2023 Q4 2023 Q3
OPERATING ACTIVITIES
Net Income -$904.0K -$3.126M
YoY Change -68.82% 83.34%
Depreciation, Depletion And Amortization $1.000K $25.00K
YoY Change
Cash From Operating Activities -$2.940M -$4.694M
YoY Change -10.42% 116.01%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00
YoY Change
Cash From Investing Activities $0.00 $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -17.00K 16.00K
YoY Change
NET CHANGE
Cash From Operating Activities -2.940M -4.694M
Cash From Investing Activities 0.000 0.000
Cash From Financing Activities -17.00K 16.00K
Net Change In Cash -2.957M -4.678M
YoY Change -9.9% 115.28%
FREE CASH FLOW
Cash From Operating Activities -$2.940M -$4.694M
Capital Expenditures $0.00 $0.00
Free Cash Flow -$2.940M -$4.694M
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.01
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.01
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.04
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.03
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
212756761
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
212466889
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
212627591
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
212466889
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
dei Entity Registrant Name
EntityRegistrantName
Rare Element Resources Ltd
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
00-0000000
dei Entity Central Index Key
EntityCentralIndexKey
0001419806
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
us-gaap Common Stock Shares Authorized Unlimited
CommonStockSharesAuthorizedUnlimited
Unlimited
CY2022 us-gaap Common Stock Shares Authorized Unlimited
CommonStockSharesAuthorizedUnlimited
Unlimited
CY2023Q3 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P12M
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y
CY2023Q3 reemf Percentage Of Total Estimated Cost For Project Covered By Funding
PercentageOfTotalEstimatedCostForProjectCoveredByFunding
0.50
CY2021Q4 reemf Percentage Of Total Estimated Cost For Project Covered By Funding
PercentageOfTotalEstimatedCostForProjectCoveredByFunding
0.5
CY2021Q4 reemf Percentage Of Total Estimated Cost For Project Covered By Funding
PercentageOfTotalEstimatedCostForProjectCoveredByFunding
0.5
CY2021Q4 reemf Percentage Of Total Estimated Cost For Project Covered By Funding
PercentageOfTotalEstimatedCostForProjectCoveredByFunding
0.5
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-34852
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
A1
dei Entity Address Address Line1
EntityAddressAddressLine1
P.O. Box 271049
dei Entity Address City Or Town
EntityAddressCityOrTown
Littleton
dei Entity Address State Or Province
EntityAddressStateOrProvince
CO
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
80127
dei City Area Code
CityAreaCode
720
dei Local Phone Number
LocalPhoneNumber
278-2460
dei Security12b Title
Security12bTitle
None
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
212858451
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6593000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
15523000
CY2023Q3 us-gaap Accounts Receivable Related Parties Current
AccountsReceivableRelatedPartiesCurrent
368000
CY2022Q4 us-gaap Accounts Receivable Related Parties Current
AccountsReceivableRelatedPartiesCurrent
174000
CY2023Q3 us-gaap Related Party Transaction Due From To Related Party Current
RelatedPartyTransactionDueFromToRelatedPartyCurrent
3243000
CY2022Q4 us-gaap Related Party Transaction Due From To Related Party Current
RelatedPartyTransactionDueFromToRelatedPartyCurrent
2142000
CY2023Q3 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
263000
CY2022Q4 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
140000
CY2023Q3 us-gaap Assets Current
AssetsCurrent
10467000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
17979000
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
30000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
15000
CY2023Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
183000
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
205000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
273000
CY2023Q3 reemf Investment In Land
InvestmentInLand
600000
CY2022Q4 reemf Investment In Land
InvestmentInLand
600000
CY2023Q3 us-gaap Assets
Assets
11485000
CY2022Q4 us-gaap Assets
Assets
18867000
CY2023Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
221000
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
227000
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
128000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
124000
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
349000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
351000
CY2023Q3 us-gaap Mine Reclamation And Closing Liability Noncurrent
MineReclamationAndClosingLiabilityNoncurrent
182000
CY2022Q4 us-gaap Mine Reclamation And Closing Liability Noncurrent
MineReclamationAndClosingLiabilityNoncurrent
132000
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
101000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
168000
CY2023Q3 us-gaap Derivative Liability Securities Sold Under Agreements To Resell Securities Loaned Gross
DerivativeLiabilitySecuritiesSoldUnderAgreementsToResellSecuritiesLoanedGross
1493000
CY2022Q4 us-gaap Derivative Liability Securities Sold Under Agreements To Resell Securities Loaned Gross
DerivativeLiabilitySecuritiesSoldUnderAgreementsToResellSecuritiesLoanedGross
1281000
CY2023Q3 us-gaap Other Long Term Debt Noncurrent
OtherLongTermDebtNoncurrent
92000
CY2023Q3 us-gaap Liabilities
Liabilities
2217000
CY2022Q4 us-gaap Liabilities
Liabilities
1932000
CY2023Q3 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2022Q4 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
212808451
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
212515951
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
136929000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
136906000
CY2023Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
29075000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
28673000
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-156736000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-148644000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
9268000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
16935000
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
11485000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
18867000
CY2023Q3 us-gaap Exploration Expense
ExplorationExpense
2508000
CY2022Q3 us-gaap Exploration Expense
ExplorationExpense
770000
us-gaap Exploration Expense
ExplorationExpense
6183000
us-gaap Exploration Expense
ExplorationExpense
2267000
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
646000
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
902000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2001000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4041000
CY2023Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
25000
CY2022Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
25000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
76000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
75000
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
3179000
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
1697000
us-gaap Operating Expenses
OperatingExpenses
8260000
us-gaap Operating Expenses
OperatingExpenses
6383000
CY2023Q3 us-gaap Interest Income Other
InterestIncomeOther
130000
CY2022Q3 us-gaap Interest Income Other
InterestIncomeOther
78000
us-gaap Interest Income Other
InterestIncomeOther
391000
us-gaap Interest Income Other
InterestIncomeOther
100000
CY2023Q3 us-gaap Accretion Expense
AccretionExpense
70000
CY2022Q3 us-gaap Accretion Expense
AccretionExpense
71000
us-gaap Accretion Expense
AccretionExpense
212000
us-gaap Accretion Expense
AccretionExpense
213000
CY2023Q3 us-gaap Interest Expense
InterestExpense
7000
CY2022Q3 us-gaap Interest Expense
InterestExpense
23000
us-gaap Interest Expense
InterestExpense
23000
us-gaap Interest Expense
InterestExpense
31000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
12000
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
8000
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
53000
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-8000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
168000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-144000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-3126000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-1705000
us-gaap Net Income Loss
NetIncomeLoss
-8092000
us-gaap Net Income Loss
NetIncomeLoss
-6527000
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.04
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.03
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
212756761
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
212466889
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
212627591
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
212466889
us-gaap Net Income Loss
NetIncomeLoss
-8092000
us-gaap Net Income Loss
NetIncomeLoss
-6527000
us-gaap Depreciation
Depreciation
1000
us-gaap Depreciation
Depreciation
1000
us-gaap Accretion Expense
AccretionExpense
212000
us-gaap Accretion Expense
AccretionExpense
213000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
75000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
74000
us-gaap Provision For Loan And Lease Losses
ProvisionForLoanAndLeaseLosses
-70000
us-gaap Provision For Loan And Lease Losses
ProvisionForLoanAndLeaseLosses
-62000
us-gaap Share Based Compensation
ShareBasedCompensation
402000
us-gaap Share Based Compensation
ShareBasedCompensation
2480000
reemf Increase Decrease In Reclamation Obligation
IncreaseDecreaseInReclamationObligation
50000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-82000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
25000
reemf Adjustments To Reconcile Net Income Loss To Cash Used In Provided By Operating Activities
AdjustmentsToReconcileNetIncomeLossToCashUsedInProvidedByOperatingActivities
-7340000
reemf Adjustments To Reconcile Net Income Loss To Cash Used In Provided By Operating Activities
AdjustmentsToReconcileNetIncomeLossToCashUsedInProvidedByOperatingActivities
-3846000
us-gaap Increase Decrease In Due From Related Parties
IncreaseDecreaseInDueFromRelatedParties
194000
us-gaap Increase Decrease In Due From Related Parties
IncreaseDecreaseInDueFromRelatedParties
21000
us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
1227000
us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
1622000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-5000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-653000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-8766000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6142000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
12000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
16000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-4000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
23000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
23000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-8747000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-6142000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
15523000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
24947000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6776000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
18805000
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6593000
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
18805000
CY2023Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
183000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6776000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
18805000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
20647000
CY2022Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
452000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-1705000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
19394000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
12307000
CY2023Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
16000
CY2023Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
71000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-3126000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
9268000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
23441000
us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
2480000
us-gaap Net Income Loss
NetIncomeLoss
-6527000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
19394000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
16935000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
23000
us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
402000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
0
us-gaap Net Income Loss
NetIncomeLoss
-8092000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
9268000
us-gaap Nature Of Operations
NatureOfOperations
<table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">1.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"> NATURE OF OPERATIONS</b></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Rare Element Resources Ltd. (“we,” “us,” “Rare Element” or the “Company”) was incorporated under the laws of the Province of British Columbia, Canada, on June 3, 1999.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Rare Element holds a 100% interest in the Bear Lodge rare earth elements project (the “Bear Lodge REE Project”) located near the town of Sundance in northeast Wyoming. The Bear Lodge REE Project consists of several large, disseminated rare earth elements (“REE”) deposits that comprise one of the highest-grade REE deposits identified in North America. In addition, to neodymium-praseodymium (“Nd/Pr”), the Bear Lodge REE Project has a favorable distribution of a number of other critical rare earth elements. The Company also holds a 100% interest in the Sundance Gold Project that is adjacent to the Bear Lodge REE Project and contains a historical inferred mineral resource primarily composed of three gold targets within the area of the Bear Lodge property. Given the Company’s longstanding focus on the Bear Lodge REE Project and the current interest in REE, the advancement of the Sundance Gold Project has been on hold since 2011 and will likely remain so for the foreseeable future.  </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company is currently focused on the advancement of a rare earth processing and separation demonstration-scale plant (the “Demonstration Plant”) project. In January 2021, a consortium of companies, of which the Company is a part, received notice from the Department of Energy (“DoE”) that the consortium had been selected for negotiation of a potential financial award for the engineering, construction and operation of a rare earth separation and processing Demonstration Plant. The consortium of companies is led by General Atomics, an affiliate of Synchron, the Company’s majority shareholder, and includes certain of General Atomics’ affiliates, and LNV, an Ardurra Group, Inc. company, as engineering and construction subcontractor. A formal proposal was submitted by the consortium in response to a published Funding Opportunity Announcement in mid-2020 for the construction and operation of a rare earth separation and processing demonstration plant utilizing proprietary technology to produce commercial-grade products. The DoE finalized the award, and an agreement was executed by the DoE’s grants/agreement officer on September 27, 2021, with an effective date of October 1, 2021. The Company, as a subrecipient of the award, along with the other consortium members, commenced work on the planning and design of the Demonstration Plant project in November 2021, with the Company’s contractual arrangement with General Atomics finalized in December 2021. The DoE funding is in the amount of $21,900 and represents approximately <span style="-sec-ix-hidden:Hidden_3AqQkxyNUEqkWwyimbBPFQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one</span></span>-half of the originally estimated costs for the Demonstration Plant. The Demonstration Plant will process already stockpiled high-grade sample materials from the Bear Lodge REE Project.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">To address the Company’s funding needs, the Company completed, in December 2021, a rights offering for gross proceeds of approximately $25,400. The Company is using the net proceeds from the rights offering primarily for the permitting, licensing, engineering, and planned construction and operation of the Demonstration Plant near the Company’s Bear Lodge REE Project. The previously noted $21,900 financial award from the DoE was expected to fund approximately <span style="-sec-ix-hidden:Hidden_Z0hDlwbOt0yTRTMVFqJN8Q;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one</span></span>-half of the expected total cost of the Demonstration Plant project, with the balance of the required funding being provided by the Company utilizing the proceeds from the rights offering, the $4,400 grant from the Wyoming Energy Authority (the “WEA”), as discussed more fully in Note 7, and other funding sources, as necessary. Due to inflationary pressures, we expect the initial Demonstration Plant project cost estimate of $43,800 to increase. We are currently evaluating project options to complete the construction, operation, and decommissioning (if necessary) of the Demonstration Plant. Potential options include changes to the project timeline and the raising of additional funds. Other options are also being explored.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">During 2022 and through the nine months ended September 30, 2023, the Company continued its work on the Demonstration Plant project. This work is expected to continue over the remainder of 2023 and through the Demonstration Plant project’s expected completion date in the early part of 2025. In December 2022, the Demonstration Plant achieved its final engineering design milestone marking the completion of the DoE’s first go/no-go decision point. The completion of this milestone was a gating event for the DoE’s continued funding as provided for in the 2021 award grant. Future gating milestones include the DoE’s National Environmental Policy Act of 1969 (NEPA) review, which is expected in the fourth quarter of 2023, and the approval to proceed with the Demonstration Plant’s construction, which is anticipated shortly thereafter. If such approval is received, construction will commence thereafter and is expected to be completed in mid-2024. Operations to process and separate the REE from the stockpiled sample materials are expected to follow the completion of the Demonstration Plant’s construction for an additional <span style="-sec-ix-hidden:Hidden_GbWC4u-evkSV_KD33k1Ovw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">eight</span></span>-to-ten-month period. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During 2023, the GA-led consortium has seen increases in the Demonstration Plant project costs, including expected final equipment costs, due to, among other factors, inflation. Accordingly, the project team has commenced discussions with the DoE and other government agencies regarding further cost-sharing opportunities to offset the increase in the anticipated project budget and further project objectives. At this time, the Company has sufficient funding to complete construction of the Demonstration Plant; however, even with the completion of the 2021 rights offering and expected receipt of the WEA grant monies, the Company may not have sufficient funds to operate the Demonstration Plant for a sufficient period to obtain the information to support a commercialization decision. Further, the Company does not have sufficient funds to progress other activities, including with respect to (i) any potential funds for continuation of the Demonstration Plant’s operation to achieve further objectives beyond the current program objectives; and (ii) funds for any feasibility studies, permitting, licensing, development, and construction related to the Bear Lodge REE Project. Therefore, the achievement of these activities will be dependent upon the receipt of additional funds through financings, off-take agreements, joint ventures, strategic transactions, financial awards, or grants. We plan to seek additional funding no later than the end of the first quarter of 2024; however, there can be no assurance that the Company will be successful in completing a financing. Ultimately, in the event the Company cannot secure additional financial resources, or complete a strategic transaction in a timely manner, the Company may need to curtail or suspend its operational plans regarding the Demonstration Plant or other initiatives, or potentially liquidate its business interests, and investors may lose all or part of their investment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">The Company has incurred losses since its inception, and further losses are anticipated in the development of its business. As of September 30, 2023, the Company had cash and cash equivalents of </span><span style="font-weight:normal;">$6,593</span><span style="font-weight:normal;">. On a comparative basis, we consumed cash of </span><span style="font-weight:normal;">$8,766</span><span style="font-weight:normal;"> during the nine months ended September 30, 2023, of which approximately </span><span style="font-weight:normal;">$7,000</span><span style="font-weight:normal;"> was used for the payment of costs associated with the Demonstration Plant project, while the remainder was used for the payment of the Company’s general and administrative expenses and other ongoing costs of sustaining its properties and mining claims. </span></p>
CY2021Q4 reemf Amount Of Potential Funding For Project
AmountOfPotentialFundingForProject
21900000
CY2021Q4 reemf Rights Offering Authorized Amount
RightsOfferingAuthorizedAmount
25400000
CY2021Q4 reemf Amount Of Potential Funding For Project
AmountOfPotentialFundingForProject
21900000
CY2021Q4 reemf Amount Of Initial Estimate For Demonstration Plant
AmountOfInitialEstimateForDemonstrationPlant
43800000
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6593000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-8766000
reemf Payments For Demonstration Plant Project Costs
PaymentsForDemonstrationPlantProjectCosts
7000000
CY2023Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
183000
CY2021Q4 reemf Amount Of Potential Funding For Project
AmountOfPotentialFundingForProject
21900000
CY2021Q4 reemf Total Allowable Costs For Planned Demonstration Funded On Cost Share Basis
TotalAllowableCostsForPlannedDemonstrationFundedOnCostShareBasis
43800000
CY2021Q4 reemf Percentage Of Expected Total Cost Of Demonstration Plant Funded By Grant
PercentageOfExpectedTotalCostOfDemonstrationPlantFundedByGrant
0.50
CY2021Q4 reemf Percentage Of Expected Total Cost Of Demonstration Plant Funded By Non Federal Entity
PercentageOfExpectedTotalCostOfDemonstrationPlantFundedByNonFederalEntity
0.50
CY2022Q4 reemf Related Party Transaction Balance Of Funds Paid
RelatedPartyTransactionBalanceOfFundsPaid
6700000
reemf Related Party Transaction Funds Transferred
RelatedPartyTransactionFundsTransferred
7000000
reemf Related Party Transaction Share Of Demonstration Plant Project Costs
RelatedPartyTransactionShareOfDemonstrationPlantProjectCosts
-10457000
CY2023Q3 us-gaap Related Party Transaction Due From To Related Party Current
RelatedPartyTransactionDueFromToRelatedPartyCurrent
3243000
CY2022Q4 us-gaap Accounts Receivable Related Parties Current
AccountsReceivableRelatedPartiesCurrent
174000
reemf Reimbursable Costs Related Party
ReimbursableCostsRelatedParty
999000
reemf Proceeds From Related Party Reimbursable Costs
ProceedsFromRelatedPartyReimbursableCosts
-805000
CY2023Q3 us-gaap Accounts Receivable Related Parties Current
AccountsReceivableRelatedPartiesCurrent
368000
us-gaap Lessee Operating Lease Existence Of Option To Extend
LesseeOperatingLeaseExistenceOfOptionToExtend
true
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.40
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
330000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.07
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
32000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
128000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
96000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
256000
CY2023Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
27000
CY2023Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
229000
us-gaap Operating Lease Payments
OperatingLeasePayments
70000
CY2023Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y
CY2023Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.12
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1020000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1830000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0154
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0171
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.23
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P8Y
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P8Y
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4160000
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.26
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2180000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.18
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1020000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.38
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1830000
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4850000
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.15
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4010000
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.28
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
4006250
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
1.29
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2605000
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
1.08
CY2023Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
843750
CY2023Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
0.48
CY2022Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
1405000
CY2022Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
1.65
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
330000
reemf Stock Issued During Period Shares Issued On Net Settlement Basis
StockIssuedDuringPeriodSharesIssuedOnNetSettlementBasis
295000
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
204000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y1M6D
CY2023Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
138000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y8M12D
CY2023Q3 reemf Share Based Compensation Arrangement By Share Based Payment Award Options Nonvested Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedIntrinsicValue
66000
reemf Share Based Compensation Arrangement By Share Based Payment Award Options Unvested Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm
P9Y1M6D
CY2023Q3 us-gaap Share Based Compensation
ShareBasedCompensation
71000
CY2022Q3 us-gaap Share Based Compensation
ShareBasedCompensation
452000
us-gaap Share Based Compensation
ShareBasedCompensation
402000
us-gaap Share Based Compensation
ShareBasedCompensation
2480000
CY2023Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
127000
CY2023Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
843750
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.35

Files In Submission

Name View Source Status
0001419806-23-000036-index-headers.html Edgar Link pending
0001419806-23-000036-index.html Edgar Link pending
reemf-20230930_cal.xml Edgar Link unprocessable
0001419806-23-000036.txt Edgar Link pending
0001419806-23-000036-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
reemf-20230930.xsd Edgar Link pending
reemf-20230930x10q.htm Edgar Link pending
reemf-20230930x10q001.jpg Edgar Link pending
reemf-20230930xex31d1.htm Edgar Link pending
reemf-20230930xex31d2.htm Edgar Link pending
reemf-20230930xex32d1.htm Edgar Link pending
reemf-20230930xex32d2.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
reemf-20230930_def.xml Edgar Link unprocessable
reemf-20230930_lab.xml Edgar Link unprocessable
reemf-20230930_pre.xml Edgar Link unprocessable
reemf-20230930x10q_htm.xml Edgar Link completed
FilingSummary.xml Edgar Link unprocessable